

Ana Marquez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2353166/publications.pdf>

Version: 2024-02-01

36
papers

765
citations

567281

15
h-index

552781

26
g-index

37
all docs

37
docs citations

37
times ranked

1596
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. <i>Rheumatology</i> , 2022, 61, 1204-1210.	1.9	7
2	Genetic overlap between type 1 diabetes and other autoimmune diseases. <i>Seminars in Immunopathology</i> , 2022, 44, 81-97.	6.1	3
3	Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1290-1300.	0.9	20
4	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. <i>Scientific Reports</i> , 2021, 11, 16163.	3.3	1
5	Approaching Shared Pathophysiology in Immune-Mediated Diseases through Functional Genomics. <i>Genes</i> , 2020, 11, 1482.	2.4	6
6	A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease. <i>Scientific Reports</i> , 2020, 10, 1862.	3.3	18
7	Leveraging Genetic Findings for Precision Medicine in Vasculitis. <i>Frontiers in Immunology</i> , 2019, 10, 1796.	4.8	7
8	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. <i>PLoS ONE</i> , 2019, 14, e0213073.	2.5	19
9	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.	2.5	3
10	Meta-analysis of ImmunoChip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. <i>Genome Medicine</i> , 2018, 10, 97.	8.2	73
11	Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis. <i>Human Molecular Genetics</i> , 2018, 27, 4333-4343.	2.9	42
12	New insights into the genetic component of non-infectious uveitis through an ImmunoChip strategy. <i>Journal of Medical Genetics</i> , 2017, 54, 38-46.	3.2	18
13	A combined large-scale meta-analysis identifies <i>COG6</i> as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 286-294.	0.9	58
14	Emerging aspects of molecular biomarkers for diagnosis, prognosis and treatment response in rheumatoid arthritis. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 663-675.	3.1	12
15	LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 208-209.	0.8	0
16	Rheumatoid arthritis response to treatment across IgG1 allotype "anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	3.5	9
17	Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. <i>Arthritis Research and Therapy</i> , 2015, 17, 102.	3.5	33
18	Specific association of <i>IL17A</i> genetic variants with panuveitis. <i>British Journal of Ophthalmology</i> , 2015, 99, 566-570.	3.9	6

#	ARTICLE	IF	CITATIONS
19	Brief Report: Association of HLA*DRB1*01 With IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2015, 67, 823-827.	5.6	35
20	Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. <i>Arthritis Research and Therapy</i> , 2014, 16, R66.	3.5	25
21	Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 1-5.	1.5	32
22	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.	2.5	17
23	Analysis of two autoimmunity genes, IRAK1 and MECP2, in giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S30-3.	0.8	1
24	IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. <i>Molecular Biology Reports</i> , 2013, 40, 4851-4856.	2.3	15
25	Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition. <i>BMC Medical Genetics</i> , 2013, 14, 52.	2.1	12
26	No Evidence of Association between Common Autoimmunity STAT4 and IL23R Risk Polymorphisms and Non-Anterior Uveitis. <i>PLoS ONE</i> , 2013, 8, e72892.	2.5	4
27	Two Functional Variants of IRF5 Influence the Development of Macular Edema in Patients with Non-Anterior Uveitis. <i>PLoS ONE</i> , 2013, 8, e76777.	2.5	3
28	Association of the FCGR3A-158F/V Gene Polymorphism with the Response to Rituximab Treatment in Spanish Systemic Autoimmune Disease Patients. <i>DNA and Cell Biology</i> , 2012, 31, 1671-1677.	1.9	18
29	Association Between -174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases. <i>DNA and Cell Biology</i> , 2012, 31, 1486-1491.	1.9	17
30	Novel Association of the Interleukin 2 Interleukin 21 Region With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 1968-1975.	0.4	51
31	Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: A Study in the Spanish population and a meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1697-1704.	1.9	21
32	Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15 Crohn's disease patients. <i>European Journal of Human Genetics</i> , 2009, 17, 1304-1308.	2.8	50
33	IL23R and IL12B polymorphisms in spanish IBD patients: No evidence of interaction. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1192-1196.	1.9	38
34	Polymorphisms in the selenoprotein S gene: lack of association with autoimmune inflammatory diseases. <i>BMC Genomics</i> , 2008, 9, 329.	2.8	35
35	Strong Protective Effect of DR3 Against Ulcerative Colitis in the Spanish Population. <i>American Journal of Gastroenterology</i> , 2007, 102, 2762-2766.	0.4	3
36	Role of the PXR gene locus in inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1484-1487.	1.9	48